Trial to Evaluate Efficacy and Safety of Lenabasum in Cystic Fibrosis

Inclusion Criteria:

1. ≥ 12 years of age at the time Informed Consent/ Assent is signed.

2. Weight ≥ 40 kg.

3. FEV1 ≥ 40% predicted and < 100% predicted in the last 12 months.

4. Physician-initiated treatment with an IV antibiotic 2 or 3 times in the last 12 months
for a new PEx or physician-initiated treatment with an IV antibiotic 1 time in the
last 12 months plus physician-initiated treatment with oral antibiotic(s) 1 or more
times in the past 12 months for a new PEX.

Exclusion Criteria:

1. Severe or unstable CF at screening or Visit 1.

2. Any of the following values for laboratory tests at screening:

1. A positive pregnancy test.

2. Hemoglobin < 10 g/dL in males and < 9 g/dL in females.

3. Neutrophils < 1.0 x 10^9 /L.

4. Platelets < 75 x 10^9/L.

5. Creatinine clearance < 50 mL/min according to Modification of Diet in Renal
Disease (MDRD) Study equation.

6. Serum transaminases > 2.5 x upper limit of normal.

3. Any medical condition or concurrent medical therapies at screening or Visit 1 that may
put the subject at greater safety risk, influence response to study drug or interfere
with study assessments.